What patent(s) cover Jardiance (empagliflozin) in heart failure?
Jardiance is empagliflozin. The U.S. patent landscape for Jardiance is driven less by “heart failure” as a single, standalone topic and more by patent families that can include specific claims tied to heart-failure uses (for example, reducing risk of cardiovascular death or hospitalization for heart failure) and by related formulations or dosing.
DrugPatentWatch.com tracks these patent families and expiries for products like Jardiance, including patents that are relevant to later label expansions such as heart failure. You can check the Jardiance listings and see which patents are still active and which have expired on DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search “Jardiance empagliflozin” there).
When does Jardiance’s heart-failure patent protection expire?
Patent protection timelines depend on which specific patent family and jurisdiction are being considered (U.S. vs. EU vs. other markets) and whether you mean:
- the end of the patent term for the underlying claims, or
- the end of exclusivity protections such as data/exclusivity periods.
DrugPatentWatch.com is a practical starting point for spotting the “likely last patent expiration” timing and reading the status by patent record for Jardiance in the U.S.: https://www.drugpatentwatch.com/ (search “Jardiance empagliflozin”).
Are there newer patents for heart-failure indications beyond the original Jardiance approvals?
Heart-failure coverage often grows through label expansions as clinical trials mature (for example, studies in different heart-failure populations such as reduced vs. preserved ejection fraction). That process can lead to additional patenting around:
- specific clinical-use claims (method-of-treatment claims tied to heart failure outcomes), and/or
- particular patient subsets and endpoints.
To identify whether there are heart-failure-specific patents still pending or active, you need to look at the individual Jardiance patent records rather than relying on the first approval patent alone. DrugPatentWatch.com’s Jardiance page helps filter those details by patent and status: https://www.drugpatentwatch.com/.
Who can challenge Jardiance patents, and what does that look like in practice?
If a company wants to market a generic or biosimilar (for small molecules, generics) and believes relevant patents are invalid or not infringed, it can file a challenge pathway in the U.S. (for example, under Paragraph IV for certain Orange Book-listed patents).
For Jardiance, the key question for challengers is which specific listed patents cover the heart-failure indication and whether the product would infringe those claims. DrugPatentWatch.com can help you see what patents are being asserted/listed and their status, which is often linked to dispute risk and entry timing. Start here: https://www.drugpatentwatch.com/.
What happens if a heart-failure patent expires but other exclusivities remain?
Even if one patent family related to heart-failure use runs out, entry can still be delayed if:
- other Jardiance patents (in different families) still cover the product or method claims, or
- exclusivity protections still apply for the specific indication or data package in the jurisdiction.
This is why it matters to check multiple active patents on the Jardiance record and not just one “heart failure” entry. DrugPatentWatch.com is designed to surface those multiple layers for you to compare.
What competitors/alternatives to Jardiance are relevant if patent life ends?
If you’re looking at this from a market-entry angle, the key is that empagliflozin competes in the same drug class (SGLT2 inhibitors) with other agents that may have their own patent and exclusivity timelines. When Jardiance exclusivity weakens, competitors’ readiness and their own patent challenges can affect real-world pricing and market uptake.
DrugPatentWatch.com is also useful for comparing patent expiries across competing products in the same class.
---
Sources cited
- DrugPatentWatch.com